Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.

Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, Baron J, Heinig S, Hoffmann E, Wegge T, Krusch M, Faltinger F, Killian S, Sprogoe K, Karpf DB, Breinholt VM, Cleemann F.

J Bone Miner Res. 2019 Jul 10. doi: 10.1002/jbmr.3824. [Epub ahead of print]

PMID:
31291476
2.

TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.

Breinholt VM, Rasmussen CE, Mygind PH, Kjelgaard-Hansen M, Faltinger F, Bernhard A, Zettler J, Hersel U.

J Pharmacol Exp Ther. 2019 Sep;370(3):459-471. doi: 10.1124/jpet.119.258251. Epub 2019 Jun 24.

PMID:
31235532

Supplemental Content

Loading ...
Support Center